[Form 4] Lifetime Brands, Inc. Insider Trading Activity
Lifetime Brands, Inc. (LCUT) – Form 4 Insider Transaction
On 20 June 2025, LCUT filed a Form 4 disclosing that independent director Rachael Jarosh was granted 27,777 shares of restricted common stock on 18 June 2025 under the company’s Amended & Restated 2000 Long-Term Incentive Plan. The award carries a one-year cliff vesting schedule expiring on the first anniversary of the grant date. Because the shares were issued as part of routine director compensation, the transaction price is reported as $0 and coded “A” (acquisition).
Following the grant, Jarosh’s direct beneficial ownership rises to 83,851 LCUT shares. No derivative securities were involved, no shares were sold or disposed, and the filing does not reference a Rule 10b5-1 trading plan. There are no accompanying financial results or valuation metrics in this filing.
From an investor perspective, the filing adds modestly to insider alignment but does not constitute an open-market purchase and is not material to share count or earnings dilution.
- Director’s equity stake rises to 83,851 shares, mildly improving shareholder alignment.
- Shares were granted rather than purchased on the open market, limiting positive signaling value.
Insights
TL;DR: Routine director stock grant; minimal market impact.
The award increases the director’s stake by roughly 49%, but the absolute share count (27,777) represents less than 0.15% of LCUT’s ~18 million shares outstanding, implying negligible dilution. Because the shares were granted, not purchased, the signal is weaker than an open-market buy. Still, additional equity ownership modestly aligns board and shareholder interests. No cash outflow or revenue impact is associated with the grant, so valuation models remain unchanged.
TL;DR: Standard equity compensation aligns incentives; neutral governance impact.
The grant follows the company’s pre-approved LTIP and standard vesting terms, suggesting strong adherence to compensation policy. One-year vesting encourages near-term board focus while retaining flexibility. Absence of a 10b5-1 plan notation is expected given the nature of the grant. There are no red flags regarding excessive compensation or accelerated vesting. Overall governance risk unchanged.